Technology
Pipeline
Intranasal Naloxone
Intranasal Epinephrine
About us
Contact
News
Investors
Overview
Press Releases
Events
SEC Filings
Corporate Governance
Stock Information
FAQs
Menu
Technology
Pipeline
Intranasal Naloxone
Intranasal Epinephrine
About us
Contact
News
Investors
Overview
Press Releases
Events
SEC Filings
Corporate Governance
Stock Information
FAQs
Nasus Pharma presented clinical results of intranasal epinephrine in EAACI, July 2022, Prague
CLICK HERE
https://www.eaaci.org/eaaci-congresses/eaaci-2022
Share this post
Previous
Nasus Pharma announces publication of its pivotal study comparing its FMXIN001 powder nasal Naloxone to Narcan®
Next
Nasus pharma presented clinical results at Fourth Annual – ASPN Conference, July 14-17, Miami Beach
